Spots Global Cancer Trial Database for Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
Official Title: Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
Study ID: NCT04984330
Study Description
Brief Summary: The purpose of this study is to test the safety and efficacy of Selinexor and Dexamethasone and see what effects it has on AL amyloidosis.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Weill Cornell Medicine - Multiple Myeloma Center, New York, New York, United States
Contact Details
Name: Cara Rosenbaum, MD
Affiliation: Weill Medical College of Cornell University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
